ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin

By Thrombogenics Nv, PRNE
Wednesday, September 29, 2010

LEUVEN, Belgium, September 30, 2010 - ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical
company focused on the discovery and development of innovative treatments for
eye disease, cardiovascular disease and cancer, announces that it has signed
a 10-year supply agreement with MSD Biologics (UK) Ltd, part of the Merck
BioManufacturing Network, for the production of microplasmin. ThromboGenics
anticipates that this deal will meet its long-term commercial needs for bulk
drug substance of this novel therapeutic agent.

Microplasmin, which is ThromboGenics' lead drug candidate,
recently completed two successful Phase III clinical trials in patients with
vitreomacular adhesion (VMA). These Phase III results demonstrated
microplasmin's potential to transform the treatment of retinal disorders.
ThromboGenics is targeting BLA submission to FDA and MAA to EMA by mid 2011.

MSD Biologics, a contract manufacturing organization with
specific expertise in microbial-derived biologics, has been producing
microplasmin for ThromboGenics since 2007, and provided the clinical bulk
substance for ThromboGenics' extensive Phase III program that recruited over
650 patients in the U.S. and Europe. MSD Biologics will produce microplasmin
at its Billingham facility (UK), which has been approved for commercial
production by the U.S. FDA and the EMA.

Microplasmin is a truncated form of the natural human protein
plasmin. ThromboGenics has created, on a proprietary basis, the first
stabilized and readily manufactured form of this molecule.

Dr. Patrik De Haes, CEO of ThromboGenics, commented, "The
signing of this 10-year supply agreement with MSD Biologics is a further
important step in our preparations to commercialize microplasmin. I am glad
that we will be continuing to work with the organization and team that have
done such a good job in providing us with the bulk microplasmin that we have
used for our successful Phase III program. With this deal in place, we remain
on track to file microplasmin with both the FDA and EMA by mid 2011 to gain
marketing approval for this exciting potential new treatment option for a
broad range of retinal disorders."

Steve Bagshaw, Site General Manager, MSD Biologics, added, "We
are delighted that ThromboGenics has chosen to continue to work with MSD
through this long term supply agreement for the production of microplasmin.
We look forward to extending our successful working relationship with them as
they progress through the next stage of commercialization plans."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the
discovery and development of innovative medicines for the treatment of eye
disease, vascular disease and cancer. The Company's lead product microplasmin
has completed two Phase III clinical trials for the non-surgical treatment of
retinal disorders. Microplasmin is also being evaluated in Phase II clinical
development for additional vitreoretinal conditions. In addition,
ThromboGenics is developing novel antibody therapeutics in collaboration with
BioInvent International; these include TB-402 (anti-Factor VIII), a long
acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for
cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company
is listed on Eurolist by Euronext Brussels under the symbol THR. More
information is available at

About Merck BioManufacturing Network

Merck BioManufacturing Network (known outside the USA and
Canada as MSD BioManufacturing Network) is a full service CMO providing
development and manufacturing services for biologics to pharmaceutical and
biotechnology companies. It comprises the operations at Billingham, UK
(formerly Avecia Biologics), and at Research Triangle Park, NC, USA (formerly
Diosynth Biotechnology). Merck is known as MSD outside USA and Canada. For
additional information about Merck BioManufacturing Network, please visit

Important information about forward-looking statements

Certain statements in this press release may be considered
"forward-looking". Such forward-looking statements are based on current
expectations, and, accordingly, entail and are influenced by various risks
and uncertainties. The Company therefore cannot provide any assurance that
such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the business and
other factors that could cause actual results to differ materially from any
forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10

    Stuart Laermer, Chief Business Officer
    Tel: +1-(212)-201-0920

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-(0)207-638-95-71

    Merck BioManufacturing Network
    Bridget Hall, MSD Biologics (UK) Ltd
    Tel : +44-(0)1642-367320

For further information please contact: ThromboGenics, Dr. Patrik De Haes, CEO, Tel: +32-16-75-13-10, patrik.dehaes at Stuart Laermer, Chief Business Officer, Tel: +1-(212)-201-0920, stuart.laermer at Citigate Dewe Rogerson, Amber Bielecka/ David Dible/ Nina Enegren, Tel: +44-(0)207-638-95-71, amber.bielecka at Merck BioManufacturing Network, Bridget Hall, MSD Biologics (UK) Ltd, Tel : +44-(0)1642-367320, bridget.hall at

Health News

ThromboGenics NV News

will not be displayed